会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明授权
    • Papillomavirus vaccines
    • 乳头瘤病毒疫苗
    • US08012679B1
    • 2011-09-06
    • US08764926
    • 1996-12-16
    • C. Richard SchlegelA. Bennett Jenson
    • C. Richard SchlegelA. Bennett Jenson
    • C12Q1/70
    • C07K14/005A61K39/00C12N2710/20022C12N2710/20034
    • Seven polyclonal and monoclonal antibodies were characterized for their ability to react specifically with either conformational or non-conformational epitopes of the HPV-1 virion. Using these antibodies, it was shown that the HPV-1 L1 protein (when expressed by an SV40 vector in cos cells) displayed conformational epitopes characteristic of intact viral particles. In addition, the L1 capsid protein was translocated normally into cell nuclei, was of appropriate size (57kD), and could be isolated in native form by immunoprecipitation techniques. Most importantly, the screening of expressed papillomavirus capsid proteins for reactivity with conformation-dependent antibodies represents a new, general methodology for ensuring that such proteins will be suitable for use in vaccine development or in the serologic detection/typing of human papillomavirus infections.
    • 表征了七种多克隆和单克隆抗体与HPV-1病毒体的构象或非构象表位特异性反应的能力。 使用这些抗体,显示HPV-1 L1蛋白质(当在COS细胞中由SV40载体表达时)显示完整病毒颗粒特征的构象表位。 此外,L1衣壳蛋白通常转位到细胞核中,具有适当的大小(57kD),并且可以通过免疫沉淀技术以天然形式分离。 最重要的是,筛选表达的乳头状瘤病毒衣壳蛋白与构象依赖性抗体的反应性代表了一种新的通用方法,用于确保这些蛋白质适用于疫苗开发或人乳头状瘤病毒感染的血清学检测/分型。